Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;31(6):760-768.
doi: 10.1016/j.annonc.2020.03.295. Epub 2020 Mar 30.

Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer

Y Jiang  1 , H Wang  2 , J Wu  2 , C Chen  3 , Q Yuan  3 , W Huang  4 , T Li  4 , S Xi  5 , Y Hu  4 , Z Zhou  6 , Y Xu  3 , G Li  7 , R Li  8
Affiliations
Free article

Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer

Y Jiang et al. Ann Oncol. 2020 Jun.
Free article

Erratum in

Abstract

Background: The tumor immune microenvironment can provide prognostic and predictive information. A previously validated ImmunoScore of Gastric Cancer (ISGC) evaluates both lymphoid and myeloid cells in the tumor core and invasive margin with immunohistochemical staining of surgical specimens. We aimed to develop a noninvasive radiomics-based predictor of ISGC.

Patients and methods: In this retrospective study including four independent cohorts of 1778 patients, we extracted 584 quantitative features from the intratumoral and peritumoral regions on contrast-enhanced computed tomography images. A radiomic signature [radiomics ImmunoScore (RIS)] was constructed to predict ISGC using regularized logistic regression. We further evaluated its association with prognosis and chemotherapy response.

Results: A 13-feature radiomic signature for ISGC was developed and validated in three independent cohorts (area under the curve = 0.786, 0.745, and 0.766). The RIS signature was significantly associated with both disease-free and overall survival in the training and all validation cohorts [hazard ratio (HR) range: 0.296-0.487, all P < 0.001]. In multivariable analysis, the RIS remained an independent prognostic factor adjusting for clinicopathologic variables (adjusted HR range: 0.339-0.605, all P < 0.003). For stage II and stage III disease, patients with a high RIS derived survival benefit from adjuvant chemotherapy {HR = 0.436 [95% confidence interval (CI) 0.253-0.753], P = 0.002; HR = 0.591 (95% CI 0.428-0.818), P < 0.001, respectively}, whereas those with a low RIS did not.

Conclusion: The RIS is a reliable tool for evaluation of immunoscore and retains the prognostic significance in gastric cancer. Future prospective studies are required to confirm its potential to predict treatment response and select patients who will benefit from chemotherapy.

Keywords: CT image; ImmunoScore; chemotherapy response; gastric cancer; immune microenvironment.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no potential conflicts of interest regarding this study.